論文種別	原著(症例報告除く)
言語種別	英語
査読の有無	その他(不明)
表題	Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey.
掲載誌名	正式名：NPJ breast cancer 略　 称：NPJ Breast Cancer ISSNコード：23744677/23744677
掲載区分	国外
巻・号・頁	11(1),pp.113
著者・共著者	Masahiro Takada, Shigehira Saji, Takayuki Ueno, Norikazu Masuda, Hiroshi Ishiguro, Takanori Ishida, Toshiaki Saeki, Shigeru Imoto, Shinji Ohno, Hiroji Iwata, Tomoharu Sugie, Kenjiro Aogi, Shin Takayama, Nobuaki Sato, Yuichiro Kai, Masahiro Kitada, Rikiya Nakamura, Kenichi Watanabe, Yutaka Matsuyama, Masakazu Toi
発行年月	2025/10
概要	This multicenter observational study investigated the prognosis of patients who participated in the Phase III POTENT trial, which examined combining S-1 with standard endocrine therapy in patients with estrogen receptor-positive, HER2-negative early breast cancer, over a longer follow-up period. The primary endpoint was overall survival (OS), with invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) as secondary endpoints. Of the 1,930 POTENT trial participants, 1,593 patients (790 for S-1 and 803 for endocrine therapy alone) were included here. The median follow-up time was 77.5 months. Fifty-one and 58 deaths were observed in the S-1 and endocrine therapy alone groups, respectively. The 6-year OS rates were similar, with 94.4% in the S-1 group and 93.1% in the endocrine therapy alone group. Overall, both endocrine therapy alone and endocrine therapy plus S-1 resulted in favorable OS. Combining S-1 with endocrine therapy maintained the previously observed benefits of IDFS and DDFS.
DOI	10.1038/s41523-025-00832-w
PMID	41136408